US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

41.92

-0.2100-0.50%

Volume:692.81K

Turnover:29.08M

Market Cap:1.80B

PE:-12.01

High:42.90

Open:42.48

Low:41.48

Close:42.13

52wk High:45.46

52wk Low:13.37

Shares:42.88M

Float Shares:21.08M

Volume Ratio:1.45

T/O Rate:3.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4892

EPS(LYR):-2.5506

ROE:-28.57%

ROA:-18.82%

PB:3.29

PE(LYR):-16.44

Loading ...

Overview Company News Filings

Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares

13D Filings -- Barrons.com

Dianthus Therapeutics Joins Evercore Healthcare Conference

Dianthus Therapeutics (DNTH): Assessing Valuation Following Positive Claseprubart Trial Results and Pipeline Progress

Simply Wall St.

Dianthus Therapeutics posts Q3 results and reports positive Phase 2 MaGic trial data in gMG

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis

Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212

Dianthus Therapeutics Inc - Reaffirms Cash Runway Into 2028

THOMSON REUTERS

Dianthus Therapeutics Inc - Under the Term, Co to Pay Leads Biolabs up to $38 Mln

THOMSON REUTERS

Dianthus Therapeutics Announces Exclusive License Agreement With Leads Biolabs for Dnth212, a First and Potentially Best-in-Class, Phase 1 Ready Bifunctional Bdca2 & Baff/April Inhibitor for Severe Autoimmune Diseases

THOMSON REUTERS

Dianthus Therapeutics Inc - Estimated Pro Forma Cash Balance at $525 Mln Following the in-Licensing of Dnth212

THOMSON REUTERS

Dianthus initiated with a Buy at Truist

Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting

Dianthus, Opendoor, and More Stocks See Action From Activist Investors -- Barrons.com

William Blair Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)

Dianthus initiated with a Buy at Clear Street

Dianthus Therapeutics Is Maintained at Buy by Stifel

Dianthus price target raised to $44 from $42 at Wedbush

Wedbush Raises Price Target on Dianthus Therapeutics to $44 From $42, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DNTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DNTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":41.92,"timestamp":1765832400000,"preClose":42.13,"halted":0,"volume":692813,"delay":0,"floatShares":21075200,"shares":42876015,"eps":-3.489224,"marketStatus":"Pre-Mkt","change":-0.21,"latestTime":"12-16 05:26:32 EST","open":42.48,"high":42.9,"low":41.48,"amount":29080285.280860003,"amplitude":0.033705,"askPrice":67.07,"askSize":200,"bidPrice":32.66,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.489224,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":41.92,"postHourTrading":{"tag":"盘后","latestPrice":41.92,"preClose":41.92,"latestTime":"17:29 EST","volume":22175,"amount":929576,"timestamp":1765837752266},"volumeRatio":1.4470757834693977,"impliedVol":0.5434,"impliedVolPercentile":0.2771},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","floatShares":21075200,"roa":"-18.82%","roe":"-28.57%","lyrEps":-2.55056,"volumeRatio":1.4470757834693977,"shares":42876015,"dividePrice":0,"high":42.9,"amplitude":0.033705,"preClose":42.13,"low":41.48,"week52Low":13.365,"pbRate":"3.29","psRate":"583.94","week52High":45.455,"institutionHeld":0,"latestPrice":41.92,"committee":-0.333333,"eps":-3.489224,"divideRate":0,"volume":692813,"delay":0,"ttmEps":-3.489224,"open":42.48,"prevYearClose":21.8,"prevWeekClose":42.13,"prevMonthClose":43.98,"prevQuarterClose":39.35,"fiveDayClose":43.6,"twentyDayClose":40.85,"sixtyDayClose":36.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"DNTH","fiscalQuarterEnding":"2025/09","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":-0.97},{"market":"US","date":"2025-08-07","symbol":"DNTH","fiscalQuarterEnding":"2025/06","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2025-05-12","symbol":"DNTH","fiscalQuarterEnding":"2025/03","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.82},{"market":"US","date":"2025-03-11","symbol":"DNTH","fiscalQuarterEnding":"2024/12","expectedEps":-0.85,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"DNTH","fiscalQuarterEnding":"2024/09","expectedEps":-0.59,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.74}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DNTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4667,"buy":0.5333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1760850000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DNTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DNTH","date":"2025-12-12","current":-12.014133,"percent":0.294776,"low":-21.520733,"twenty":-14.759182,"median":-10.582949,"eighty":-5.885547,"high":-2.378652,"avg":-10.500069,"sd":4.394323,"marketCap":1784928504},"quantilePoints":[{"date":"2023-09-22","current":-6.821887,"twenty":-6.869759,"median":-6.842701,"eighty":-6.807317,"marketCap":194260047},{"date":"2023-09-29","current":-5.576152,"twenty":-6.838538,"median":-5.576152,"eighty":-5.435929,"marketCap":201460812},{"date":"2023-10-06","current":-4.920135,"twenty":-6.800032,"median":-5.4757,"eighty":-5.354747,"marketCap":177759540},{"date":"2023-10-13","current":-4.916034,"twenty":-6.077097,"median":-5.403948,"eighty":-4.942276,"marketCap":177611407},{"date":"2023-10-20","current":-5.11694,"twenty":-5.587632,"median":-5.309646,"eighty":-5.016077,"marketCap":184869921},{"date":"2023-10-27","current":-4.75613,"twenty":-5.576152,"median":-5.262494,"eighty":-4.957036,"marketCap":171834222},{"date":"2023-11-03","current":-4.920135,"twenty":-5.49415,"median":-5.12514,"eighty":-4.920135,"marketCap":177759540},{"date":"2023-11-10","current":-4.678228,"twenty":-5.457249,"median":-5.084139,"eighty":-4.879133,"marketCap":169019695},{"date":"2023-11-17","current":-3.935775,"twenty":-5.444949,"median":-4.957036,"eighty":-4.76023,"marketCap":169663374},{"date":"2023-11-24","current":-4.021709,"twenty":-5.412148,"median":-4.920135,"eighty":-4.674948,"marketCap":173367815},{"date":"2023-12-01","current":-3.842966,"twenty":-5.377707,"median":-4.920135,"eighty":-3.993522,"marketCap":165662579},{"date":"2023-12-08","current":-3.640162,"twenty":-5.338346,"median":-4.907834,"eighty":-3.949524,"marketCap":156920099},{"date":"2023-12-15","current":-2.684576,"twenty":-5.297345,"median":-4.846332,"eighty":-3.884902,"marketCap":115726721},{"date":"2023-12-22","current":-3.007688,"twenty":-5.267824,"median":-4.788931,"eighty":-3.85534,"marketCap":129655417},{"date":"2023-12-29","current":-3.482043,"twenty":-5.235843,"median":-4.75818,"eighty":-3.842966,"marketCap":150103929},{"date":"2024-01-05","current":-4.482315,"twenty":-5.235843,"median":-4.715129,"eighty":-3.861528,"marketCap":193223616},{"date":"2024-01-12","current":-4.05952,"twenty":-5.169421,"median":-4.670027,"eighty":-3.873902,"marketCap":174997769},{"date":"2024-01-19","current":-3.952961,"twenty":-5.12186,"median":-4.521845,"eighty":-3.879402,"marketCap":170404263},{"date":"2024-01-26","current":-6.135656,"twenty":-5.267824,"median":-4.661827,"eighty":-3.893152,"marketCap":264495873},{"date":"2024-02-02","current":-14.091886,"twenty":-5.428549,"median":-4.735629,"eighty":-3.901401,"marketCap":607473021},{"date":"2024-02-09","current":-15.77856,"twenty":-5.593373,"median":-4.788931,"eighty":-3.913775,"marketCap":680182147},{"date":"2024-02-16","current":-16.247836,"twenty":-6.141843,"median":-4.875033,"eighty":-3.933712,"marketCap":700411702},{"date":"2024-02-23","current":-16.322648,"twenty":-6.585949,"median":-4.911934,"eighty":-3.935775,"marketCap":703636704},{"date":"2024-03-01","current":-16.832731,"twenty":-6.855189,"median":-4.920135,"eighty":-3.939212,"marketCap":725625351},{"date":"2024-03-08","current":-17.220393,"twenty":-14.108208,"median":-4.920135,"eighty":-3.952961,"marketCap":742336722},{"date":"2024-03-15","current":-18.274564,"twenty":-15.869694,"median":-5.055438,"eighty":-3.952961,"marketCap":787779926},{"date":"2024-03-22","current":-19.002283,"twenty":-16.27504,"median":-5.103895,"eighty":-3.958461,"marketCap":819150396},{"date":"2024-03-28","current":-20.617859,"twenty":-16.390659,"median":-5.12104,"eighty":-3.98046,"marketCap":898010856},{"date":"2024-04-05","current":-16.662734,"twenty":-16.662734,"median":-5.235843,"eighty":-3.987335,"marketCap":725745374},{"date":"2024-04-12","current":-16.777278,"twenty":-16.777278,"median":-5.350646,"eighty":-3.990772,"marketCap":730734324},{"date":"2024-04-19","current":-15.922581,"twenty":-16.832731,"median":-5.444949,"eighty":-3.99421,"marketCap":693508032},{"date":"2024-04-26","current":-14.143673,"twenty":-16.777278,"median":-5.535151,"eighty":-4.021709,"marketCap":616027659},{"date":"2024-05-03","current":-16.178636,"twenty":-16.662734,"median":-5.637242,"eighty":-4.021709,"marketCap":704660510},{"date":"2024-05-10","current":-14.570862,"twenty":-16.662734,"median":-6.140812,"eighty":-4.049207,"marketCap":731661246},{"date":"2024-05-17","current":-15.342363,"twenty":-16.621896,"median":-6.530951,"eighty":-4.05952,"marketCap":770401432},{"date":"2024-05-24","current":-12.724299,"twenty":-16.45867,"median":-6.737265,"eighty":-4.100768,"marketCap":638937940},{"date":"2024-05-31","current":-12.098897,"twenty":-16.404261,"median":-6.842701,"eighty":-4.106268,"marketCap":607534008},{"date":"2024-06-07","current":-12.233329,"twenty":-16.390659,"median":-12.098897,"eighty":-4.121392,"marketCap":614284386},{"date":"2024-06-14","current":-15.75779,"twenty":-16.354335,"median":-12.233329,"eighty":-4.176389,"marketCap":791261684},{"date":"2024-06-21","current":-15.114854,"twenty":-16.327131,"median":-12.630781,"eighty":-4.296009,"marketCap":758977268},{"date":"2024-06-28","current":-14.565435,"twenty":-16.324142,"median":-12.706764,"eighty":-4.381256,"marketCap":731388767},{"date":"2024-07-05","current":-15.459702,"twenty":-16.325636,"median":-12.794437,"eighty":-4.452753,"marketCap":776293455},{"date":"2024-07-12","current":-16.932611,"twenty":-16.417863,"median":-13.066224,"eighty":-4.47819,"marketCap":850254116},{"date":"2024-07-15","current":-16.920921,"twenty":-16.466954,"median":-13.180199,"eighty":-4.480252,"marketCap":849667127},{"date":"2024-08-02","current":-16.371502,"twenty":-16.45867,"median":-13.180199,"eighty":-4.482315,"marketCap":822078626},{"date":"2024-08-09","current":-13.845994,"twenty":-16.50009,"median":-13.738229,"eighty":-4.561374,"marketCap":784804801},{"date":"2024-08-16","current":-15.438194,"twenty":-16.45867,"median":-13.792112,"eighty":-4.661827,"marketCap":875052279},{"date":"2024-08-23","current":-14.304023,"twenty":-16.390659,"median":-14.112289,"eighty":-4.678228,"marketCap":810766318},{"date":"2024-08-30","current":-14.899592,"twenty":-16.390659,"median":-14.219338,"eighty":-4.715129,"marketCap":844523786},{"date":"2024-09-06","current":-14.490462,"twenty":-16.375333,"median":-14.311791,"eighty":-4.74793,"marketCap":821333873},{"date":"2024-09-13","current":-14.402421,"twenty":-16.338396,"median":-14.319559,"eighty":-4.75941,"marketCap":816343639},{"date":"2024-09-20","current":-14.552608,"twenty":-16.324142,"median":-14.311791,"eighty":-4.783191,"marketCap":824856392},{"date":"2024-09-27","current":-13.993291,"twenty":-16.306326,"median":-14.304023,"eighty":-4.815172,"marketCap":793153726},{"date":"2024-10-04","current":-14.221161,"twenty":-16.285922,"median":-14.291076,"eighty":-4.861093,"marketCap":806069627},{"date":"2024-10-11","current":-14.672555,"twenty":-16.269355,"median":-14.319559,"eighty":-4.877493,"marketCap":831655088},{"date":"2024-10-18","current":-14.522306,"twenty":-16.254626,"median":-14.311791,"eighty":-4.902094,"marketCap":823138846},{"date":"2024-10-25","current":-14.475677,"twenty":-16.248614,"median":-14.360865,"eighty":-4.914394,"marketCap":820495874},{"date":"2024-10-31","current":-14.486039,"twenty":-16.239675,"median":-14.366036,"eighty":-4.918495,"marketCap":821083201},{"date":"2024-11-08","current":-13.087312,"twenty":-16.213004,"median":-14.381745,"eighty":-4.920135,"marketCap":878053924},{"date":"2024-11-15","current":-11.244659,"twenty":-16.189942,"median":-14.360865,"eighty":-4.920135,"marketCap":754426637},{"date":"2024-11-22","current":-8.941908,"twenty":-16.180782,"median":-14.311791,"eighty":-4.920135,"marketCap":599930480},{"date":"2024-11-29","current":-10.582949,"twenty":-16.17095,"median":-14.273283,"eighty":-4.920135,"marketCap":710031190},{"date":"2024-12-06","current":-10.437372,"twenty":-16.142849,"median":-14.241876,"eighty":-4.934895,"marketCap":700264191},{"date":"2024-12-13","current":-10.36679,"twenty":-16.097823,"median":-14.188265,"eighty":-4.996397,"marketCap":695528677},{"date":"2024-12-20","current":-10.163866,"twenty":-16.05809,"median":-14.112289,"eighty":-5.061998,"marketCap":681914073},{"date":"2024-12-27","current":-10.14622,"twenty":-16.019613,"median":-14.091886,"eighty":-5.076759,"marketCap":680730195},{"date":"2025-01-03","current":-10.234448,"twenty":-15.922581,"median":-13.957579,"eighty":-5.096439,"marketCap":686649588},{"date":"2025-01-10","current":-11.284361,"twenty":-15.89482,"median":-13.822388,"eighty":-5.108369,"marketCap":757090364},{"date":"2025-01-17","current":-8.474299,"twenty":-15.887478,"median":-13.728741,"eighty":-5.115822,"marketCap":568557697},{"date":"2025-01-24","current":-9.828599,"twenty":-15.834329,"median":-13.708453,"eighty":-5.12186,"marketCap":659420380},{"date":"2025-01-31","current":-9.603618,"twenty":-15.788231,"median":-13.553088,"eighty":-5.191562,"marketCap":644325928},{"date":"2025-02-07","current":-10.128574,"twenty":-15.779567,"median":-13.462457,"eighty":-5.235843,"marketCap":679546316},{"date":"2025-02-14","current":-10.644708,"twenty":-15.766098,"median":-13.180199,"eighty":-5.267824,"marketCap":714174765},{"date":"2025-02-21","current":-10.455018,"twenty":-15.745542,"median":-13.087312,"eighty":-5.305545,"marketCap":701448070},{"date":"2025-02-28","current":-9.285997,"twenty":-15.702913,"median":-12.81575,"eighty":-5.346546,"marketCap":623016113},{"date":"2025-03-07","current":-10.375613,"twenty":-15.663831,"median":-12.724299,"eighty":-5.384267,"marketCap":696120616},{"date":"2025-03-14","current":-8.045567,"twenty":-15.60664,"median":-12.588406,"eighty":-5.420348,"marketCap":683623809},{"date":"2025-03-21","current":-7.727979,"twenty":-15.500032,"median":-12.233329,"eighty":-5.449869,"marketCap":656638658},{"date":"2025-03-28","current":-7.512473,"twenty":-15.459702,"median":-12.013661,"eighty":-5.472009,"marketCap":638327306},{"date":"2025-04-04","current":-6.416037,"twenty":-15.451099,"median":-11.624039,"eighty":-5.526951,"marketCap":545164287},{"date":"2025-04-11","current":-5.898066,"twenty":-15.431979,"median":-11.290978,"eighty":-5.587632,"marketCap":501152792},{"date":"2025-04-17","current":-7.175981,"twenty":-15.413286,"median":-11.262304,"eighty":-5.60754,"marketCap":609735897},{"date":"2025-04-25","current":-8.026663,"twenty":-15.369114,"median":-11.0285,"eighty":-5.622077,"marketCap":682017550},{"date":"2025-05-02","current":-8.204554,"twenty":-15.321347,"median":-10.898364,"eighty":-5.689407,"marketCap":697132746},{"date":"2025-05-09","current":-7.796217,"twenty":-15.230244,"median":-10.759405,"eighty":-5.898822,"marketCap":662436738},{"date":"2025-05-16","current":-5.986178,"twenty":-15.201008,"median":-10.704262,"eighty":-5.916298,"marketCap":602999662},{"date":"2025-05-23","current":-5.861665,"twenty":-15.193619,"median":-10.675588,"eighty":-5.916298,"marketCap":590457269},{"date":"2025-05-30","current":-5.698841,"twenty":-15.181369,"median":-10.600594,"eighty":-5.861665,"marketCap":574055678},{"date":"2025-06-06","current":-5.92871,"twenty":-15.126544,"median":-10.582949,"eighty":-5.698841,"marketCap":597210865},{"date":"2025-06-13","current":-6.15858,"twenty":-15.114854,"median":-10.503543,"eighty":-5.724382,"marketCap":620366052},{"date":"2025-06-20","current":-5.567944,"twenty":-15.086799,"median":-10.455018,"eighty":-5.687986,"marketCap":560870086},{"date":"2025-06-27","current":-5.788235,"twenty":-15.056571,"median":-10.424138,"eighty":-5.643102,"marketCap":583060473},{"date":"2025-07-03","current":-6.018104,"twenty":-15.025316,"median":-10.371201,"eighty":-5.641637,"marketCap":606215660},{"date":"2025-07-11","current":-6.580007,"twenty":-15.002134,"median":-10.30503,"eighty":-5.677131,"marketCap":662817229},{"date":"2025-07-18","current":-6.496998,"twenty":-14.98745,"median":-10.28959,"eighty":-5.714166,"marketCap":654455633},{"date":"2025-07-25","current":-6.956737,"twenty":-14.950568,"median":-10.234448,"eighty":-5.730129,"marketCap":700766007},{"date":"2025-08-01","current":-6.599162,"twenty":-14.912021,"median":-10.163866,"eighty":-5.73396,"marketCap":664746827},{"date":"2025-08-08","current":-6.113883,"twenty":-14.897039,"median":-10.14622,"eighty":-5.764609,"marketCap":615863655},{"date":"2025-08-15","current":-5.680098,"twenty":-14.891675,"median":-10.102106,"eighty":-5.714166,"marketCap":651813986},{"date":"2025-08-22","current":-6.633794,"twenty":-14.884329,"median":-10.031524,"eighty":-5.730129,"marketCap":761254359},{"date":"2025-08-29","current":-6.959172,"twenty":-14.857999,"median":-9.84404,"eighty":-5.73396,"marketCap":798592839},{"date":"2025-09-05","current":-6.917097,"twenty":-14.83641,"median":-9.826394,"eighty":-5.754393,"marketCap":793764587},{"date":"2025-09-12","current":-10.61968,"twenty":-14.806372,"median":-9.828599,"eighty":-5.786319,"marketCap":1218650741},{"date":"2025-09-19","current":-13.100588,"twenty":-14.770844,"median":-9.916203,"eighty":-5.789512,"marketCap":1503344826},{"date":"2025-09-26","current":-12.079369,"twenty":-14.762402,"median":-10.031524,"eighty":-5.797813,"marketCap":1386155868},{"date":"2025-10-03","current":-12.446738,"twenty":-14.758601,"median":-10.102106,"eighty":-5.811222,"marketCap":1428312952},{"date":"2025-10-10","current":-11.711999,"twenty":-14.750427,"median":-10.14622,"eighty":-5.817199,"marketCap":1343998784},{"date":"2025-10-17","current":-12.133294,"twenty":-14.726754,"median":-10.163866,"eighty":-5.821144,"marketCap":1392344064},{"date":"2025-10-24","current":-11.213186,"twenty":-14.705712,"median":-10.234448,"eighty":-5.826546,"marketCap":1286757972},{"date":"2025-10-31","current":-11.371593,"twenty":-14.704884,"median":-10.28959,"eighty":-5.834208,"marketCap":1304935797},{"date":"2025-11-07","current":-11.48051,"twenty":-14.703303,"median":-10.30503,"eighty":-5.84678,"marketCap":1450505040},{"date":"2025-11-14","current":-12.047161,"twenty":-14.690699,"median":-10.355761,"eighty":-5.85115,"marketCap":1522098532},{"date":"2025-11-21","current":-13.706615,"twenty":-14.666007,"median":-10.410904,"eighty":-5.857834,"marketCap":1731762245},{"date":"2025-11-28","current":-14.924905,"twenty":-14.703472,"median":-10.441784,"eighty":-5.865182,"marketCap":1885687139},{"date":"2025-12-05","current":-15.172635,"twenty":-14.705712,"median":-10.501337,"eighty":-5.879885,"marketCap":1916986630},{"date":"2025-12-12","current":-14.127417,"twenty":-14.759182,"median":-10.582949,"eighty":-5.885547,"marketCap":1784928504}],"updateTime":1765861819237},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589617846","title":"Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589617846","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589617846?lang=en_us&edition=fundamental","pubTime":"2025-12-06 09:00","pubTimestamp":1764982834,"startTime":"0","endTime":"0","summary":"Ryan Savitz, CFO & CBO of Dianthus Therapeutics Inc., has reported the disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL8NDQjH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics CFO & CBO Ryan Savitz Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2589432528","title":"13D Filings -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589432528","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589432528?lang=en_us&edition=fundamental","pubTime":"2025-12-06 07:35","pubTimestamp":1764977700,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 27 through Dec. 3, 2025. Source: VerityData. Insight Enterprises ValueAct Capital lowered its stake in the enterprise information-technology company to 1,446,739 shares. ValueAct Capital did so through the sale of 220,000 Insight Enterprises shares from Oct. 29 through Dec. 1 at per share prices ranging from $85 to $105.09. Following the latest sales, ValueAct Capital continues to own 4.7% of Insight Enterprises' outstanding stock, placing ValueAct below the 5% threshold that would require it to report further sales. Shares of Insight Enterprises have lost approximately 40.6% of their value since the beginning of this","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4140","BK4109","BK4595","BK4600","CNTA","ASH","USDT.USD.CC","NSIT","BK4023","DNTH","LU2463526074.USD","BK4139","BK4539","USDT.USD.HKCC","BTDR","BK4535"],"gpt_icon":0},{"id":"2585618734","title":"Dianthus Therapeutics Joins Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585618734","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585618734?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985624,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. CEO Marino Garcia is scheduled to take part in a fireside chat on Tuesday, December 2, 2025, at 2:35 p.m. ET and will also hold one-on-one meetings with investors. A webcast of the presentation will be available on the company's website in the Investors section under \"News and Events.\". Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLc16kvh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4112","BK4588","BK4127","DNTH","LU0314104364.USD","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","EVR","NDAQ","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2582330761","title":"Dianthus Therapeutics (DNTH): Assessing Valuation Following Positive Claseprubart Trial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2582330761","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582330761?lang=en_us&edition=fundamental","pubTime":"2025-11-11 14:18","pubTimestamp":1762841905,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (DNTH) caught investor attention after announcing statistically significant positive results from its Phase 2 trial for claseprubart in generalized myasthenia gravis. The company now plans to launch Phase 3 studies.\nSee our latest analysis for Dianthus Therapeutics.\nThe market has clearly taken notice of Dianthus Therapeutics’ recent milestones. The share price is up nearly 84% over the past 90 days, and there has been a robust year-to-date increase of 58% following...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-assessing-valuation-following-pos","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnth/dianthus-therapeutics/news/dianthus-therapeutics-dnth-assessing-valuation-following-pos","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNTH","PRGS","BK4097","BK4139","LU2065732104.USD"],"gpt_icon":0},{"id":"2581091537","title":"Dianthus Therapeutics posts Q3 results and reports positive Phase 2 MaGic trial data in gMG","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091537?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:02","pubTimestamp":1762376523,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. reported a net loss of $36.8 million, or $0.97 per share, for the quarter ended September 30, 2025, compared to a net loss of $25.2 million, or $0.74 per share, for the same period in 2024. The company estimates an adjusted cash, cash equivalents, and investments position of approximately $525.0 million as of September 30, 2025, after accounting for upfront and near-term milestone payments related to the licensing of DNTH212 from Nanjing Leads Biolabs. This cash position is projected to provide funding runway into 2028. Recent business developments include the closing of an upsized public offering raising about $288.0 million and the exclusive licensing agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL6WMYYk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","DNTH","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2581709464","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709464","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709464?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376460,"startTime":"0","endTime":"0","summary":"Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living , Quantitative Myasthenia Gravis , and other efficacy measures at Week 13 in Phase 2 MaGic trial in gMG. New claseprubart data from the MaGic open-label extension supporting potential for 300mg/2mL Q4W dosing and new in vitro data highlighting potential efficacy benefits of upstream  vs. downstream  complement inhibition were presented during the AANEM Annual Meeting in October 2025. Phase 3 gMG trial including two claseprubart treatment arms, 300mg/2mL Q2W and 300mg/2mL Q4W, vs. placebo anticipated to initiate in 2026. Accelerated timing for interim responder analysis for Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy ; now anticipated in Q2'26  due to faster than expected enrollment. Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy  ongoing; top-line results anticipated in 2H'26. Annou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4539","MGC","DNTH","BK4007"],"gpt_icon":0},{"id":"2579180997","title":"Dianthus Therapeutics Announces Positive Phase 2 Claseprubart Data in Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2579180997","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579180997?lang=en_us&edition=fundamental","pubTime":"2025-10-30 03:30","pubTimestamp":1761766226,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. has announced new data from its Phase 2 MaGic trial evaluating claseprubart in patients with generalized Myasthenia Gravis . The results, including new open-label extension data, were presented during the Myasthenia Gravis Foundation of America  Scientific Session at the 2025 American Association of Neuromuscular and Electromagnetic Medicine  Annual Meeting. The company highlighted the potential of 300mg/2mL Q4W dosing of claseprubart and plans to initiate a Phase 3 trial in 2026. The upcoming Phase 3 study will include two claseprubart treatment arms  versus placebo, with a QMG ≥10 screening criterion. Dianthus also presented preclinical in vitro data suggesting efficacy benefits of upstream  inhibition with claseprubart compared to downstream  inhibition. Further details and a replay of the virtual industry forum are available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL8c64qp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD","DNTH","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","BK4585","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2575710580","title":"Dianthus Therapeutics announces exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710580","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710580?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612417,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. announced it has entered into an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor. Under the terms of the agreement, Dianthus will pay Leads Biolabs up to $38 million, including $30 million in upfront and near-term milestone payments and an additional $8 million milestone upon initiation of a Dianthus-led Phase 1 study. Leads Biolabs is also eligible to receive up to $962 million in development, regulatory approval, and sales-based milestones, as well as tiered royalties on ex-Greater China net sales. Dianthus will hold exclusive rights to develop and commercialize DNTH212 globally outside of Greater China. The company estimates a pro forma cash balance of approximately $525 million following the transaction and reaffirms its cash runway into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL2cr6SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210150020.SGD","DNTH","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","NDAQ","BK4585","BK4139"],"gpt_icon":0},{"id":"2575710658","title":"Dianthus Therapeutics Inc - Reaffirms Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710658?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA4VLTFW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2575710635","title":"Dianthus Therapeutics Inc - Under the Term, Co to Pay Leads Biolabs up to $38 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2575710635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575710635?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA4VLTFW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2575358710","title":"Dianthus Therapeutics Announces Exclusive License Agreement With Leads Biolabs for Dnth212, a First and Potentially Best-in-Class, Phase 1 Ready Bifunctional Bdca2 & Baff/April Inhibitor for Severe Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2575358710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575358710?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA4VLTFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2575106627","title":"Dianthus Therapeutics Inc - Estimated Pro Forma Cash Balance at $525 Mln Following the in-Licensing of Dnth212","url":"https://stock-news.laohu8.com/highlight/detail?id=2575106627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575106627?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:00","pubTimestamp":1760612401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nTUA4VLTFW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2575296556","title":"Dianthus initiated with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2575296556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575296556?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:10","pubTimestamp":1760436633,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill initiated coverage of Dianthus (DNTH) with a Buy rating and $56 price target The recent Phase 2 proof-of-concept resu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dianthus-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dianthus-initiated-with-a-buy-at-truist-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2572514951","title":"Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514951","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514951?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:00","pubTimestamp":1759406425,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Announces Positive Phase 2 Results for Claseprubart in Generalized Myasthenia Gravis; Data to Be Presented at 2025 AANEM Annual Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL6Dl5K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","DNTH","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4139","BK4585","BK4112","BK4588"],"gpt_icon":0},{"id":"2568295439","title":"Dianthus, Opendoor, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2568295439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568295439?lang=en_us&edition=fundamental","pubTime":"2025-09-20 03:26","pubTimestamp":1758309960,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Sept. 11 through Sept. 17, 2025. Source: VerityData. Opendoor Technologies  Access Industries reduced its stake in the real estate tech platform to 42,724,914 shares. Access Industries did so through the open market sale of 10,874,000 Opendoor Technologies shares on Sept. 12, 2025, at per share prices ranging from $8.77 to $9.77. On Sept. 10, director Pueo Keffer, who oversees venture capital at Access Industries, informed the board of his decision to retire from his position, effective immediately. Following the latest sales, Access continu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4216","LTH","BK4079","BK4139","ISBC","DHT","DNTH","BK4561","VVX","BK4144","OPEN","BK4211","BK4187","BK4562"],"gpt_icon":1},{"id":"2568632664","title":"William Blair Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568632664","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568632664?lang=en_us&edition=fundamental","pubTime":"2025-09-17 15:25","pubTimestamp":1758093912,"startTime":"0","endTime":"0","summary":"In a report released on September 13, Matt Phipps from William Blair reiterated a Buy rating on Dianthus Therapeutics. The company’s shares closed ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-keeps-their-buy-rating-on-dianthus-therapeutics-dnth-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-keeps-their-buy-rating-on-dianthus-therapeutics-dnth-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNTH"],"gpt_icon":0},{"id":"2568351084","title":"Dianthus initiated with a Buy at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2568351084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568351084?lang=en_us&edition=fundamental","pubTime":"2025-09-17 04:25","pubTimestamp":1758054318,"startTime":"0","endTime":"0","summary":"Clear Street analyst Bill Maughan initiated coverage of Dianthus (DNTH) with a Buy rating and $100 price target Dianthus is a biotech company prima...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dianthus-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dianthus-initiated-with-a-buy-at-clear-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2566697054","title":"Dianthus Therapeutics Is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2566697054","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566697054?lang=en_us&edition=fundamental","pubTime":"2025-09-12 22:42","pubTimestamp":1757688120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DNTH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 10:42 ET (14:42 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","LENZ","SF"],"gpt_icon":0},{"id":"2566976637","title":"Dianthus price target raised to $44 from $42 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2566976637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566976637?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:36","pubTimestamp":1757676968,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Dianthus (DNTH) to $44 from $42 and keeps an Outperform rating on the shares. The firm is incorporating t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dianthus-price-target-raised-to-44-from-42-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dianthus-price-target-raised-to-44-from-42-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2566731569","title":"Wedbush Raises Price Target on Dianthus Therapeutics to $44 From $42, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2566731569","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566731569?lang=en_us&edition=fundamental","pubTime":"2025-09-12 18:41","pubTimestamp":1757673714,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $60.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DNTH","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}